Association Between Antihypertensive Use and Hospitalized Pneumonia in Patients With Stroke: A Korean Nationwide Population-Based Cohort Study

Jae-Hyun Yun,1 Seung Yeon Rhee,2 Sungyoun Chun,1 Hyoung Seop Kim,2 and Byung-Mo Oh1,4,5

1Department of Rehabilitation Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
2Department of Physical Medicine and Rehabilitation, National Health Insurance Service Ilsan Hospital, Goyang, Korea
3Department of Research and Analysis Team, National Health Insurance Service Ilsan Hospital, Goyang, Korea
4National Traffic Injury Rehabilitation Hospital, Yangpyeong, Korea
5Institute on Aging, Seoul National University, Seoul, Korea

Background: We aimed to examine the association between antihypertensive use and the incidence of hospitalized pneumonia in patients with a history of stroke.

Methods: In this case-crossover study, we obtained data from the Korean National Health Insurance Service–National Sample Cohort database. We included the data of patients with history of stroke who were admitted with a disease code of pneumonia. We analyzed the patients' exposure to antihypertensives in the 30 (single case period), 90–120, and 150–180 days (2 control periods) before the onset of pneumonia using conditional logistic regression analysis. Additionally, sensitivity analysis and subgroup analysis according to diabetes status, age, and documented disability were performed.

Results: Angiotensin II receptor blocker (ARB) use was associated with a reduced risk of hospitalized pneumonia (adjusted odds ratio [OR] [95% confidence interval; 95% CI]: 0.718 [0.576–0.894]). However, the use of angiotensin converting enzyme inhibitors and other antihypertensives were not associated with a change in hospitalized pneumonia incidence (adjusted OR [95% CI]: 0.902, [0.603–1.350] and 0.788 [0.609–1.018], respectively). Subgroup analysis revealed that ARB use was associated with a reduced incidence of hospitalized pneumonia in patients with a history of stroke who were admitted with a disease code of pneumonia. We analyzed the patients’ exposure to antihypertensives in the 30 (single case period), 90–120, and 150–180 days (2 control periods) before the onset of pneumonia using conditional logistic regression analysis. Additionally, sensitivity analysis and subgroup analysis according to diabetes status, age, and documented disability were performed.

Conclusion: ARB use is associated with a reduced incidence of hospitalized pneumonia in patients with a history of stroke, especially in older adults.

Keywords: Pneumonia; Stroke; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents
INTRODUCTION

Pneumonia is a leading cause of mortality and morbidity; its rank has risen from 10th to 3rd in recent decades. In South Korea, pneumonia was 6th most common cause of death in 2010, with 14.9 deaths per 100,000 population, but in 2020, it was the 3rd most common cause of death, and the rate of mortality from pneumonia increased to 43.3 deaths per 100,000 population. Attention should be paid to pneumonia in patients with stroke. Pneumonia and urinary tract infection commonly occur after stroke and have a considerable impact on clinical outcome. Because of the high mortality rate associated with pneumonia, it is vital to determine strategies to prevent pneumonia in patients with stroke.

As hypertension is the biggest risk factor for stroke, antihypertensives are frequently prescribed to patients with stroke. Associations between the use of antihypertensives, particularly angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), and the risk of pneumonia have been reported in the past 2 decades. Despite numerous studies on this topic, the effects of antihypertensives on pneumonia remain controversial. Moreover, no study has been conducted on the effect of antihypertensives on pneumonia in a Korean population.

By using a national sample cohort comprising 1 million South Korean individuals, we aimed to assess the association between the use of antihypertensives and the incidence of hospitalized pneumonia in patients with a history of stroke. Additionally, we investigated the effects of antihypertensive use according to age, diabetes mellitus status, and disability. By doing so, we attempted to identify antihypertensives that can help prevent post-stroke hospitalized pneumonia.

METHODS

Data source

We obtained data from the Korean National Health Insurance Service-National Sample Cohort database. It contains information from 2002 to 2015 on 1 million South Korean individuals, accounting for 2.2% of the entire population of 50 million. It primarily contains anonymized data on the diagnosis, medications, degree of disability, income (socio-economic variables), and history of hospitalization, including duration of hospitalization, date of admission and discharge, and medical examination findings. The approved database access request ID was REQ000025162-001.

Study design and participants

In this case-crossover study, we included patients aged over 18 years with a diagnosis of ischemic stroke (International Classification of Diseases 10th Revision [ICD-10] codes: I60, I61, I62, I63, and G45), who had been hospitalized due to pneumonia (ICD-10 codes: J12-18) after stroke between 2002 and 2013.

We assessed the association between 3 categories of antihypertensives (ACE inhibitor, ARB, and others) and the incidence of hospitalized pneumonia in stroke survivors. A case-crossover study design is used to evaluate associations of incidences of acute disease and specific exposures. Each patient served as their own control. Thus, confounding factors that could arise from personal characteristics were minimized.
The date of the first incidence of pneumonia was defined as the “index date.” The case period was defined as the 30-day period before the index date. The status of exposure to antihypertensive drugs in this period was considered to affect the incidence of pneumonia. We defined the 2 control periods as the periods 90–120 days and 150–180 days before the index date. We considered the status of exposure to antihypertensive drugs in the control periods to be irrelevant to the incidence of pneumonia (Fig. 1). Considering the possibility of poor medication adherence, a washout period was included between the case and control periods.

In each participant, we adjusted for confounding factors, including time-varying confounding factors such as the history of exposure to other medications that could affect the incidence of pneumonia and the number of outpatient visits.

**Medication history**
We investigated the use of ACE inhibitors, ARBs, or other antihypertensives during each case and control period. We classified drug combinations including ACE inhibitors as “ACE inhibitors” and those including ARBs as “ARBs.” Other antihypertensives included calcium channel blockers, alpha blockers, beta blockers, alpha-beta blockers, and diuretics. In addition, we assessed concomitant use of medications such as statins, antipsychotics, and benzodiazepines, which could affect the incidence of pneumonia, using the 2019 Korea medication list published by the National Health Insurance Review and Assessment Service (Supplementary Table 1).

**Sensitivity and subgroup analyses**
To increase the robustness of the study findings, we conducted sensitivity analysis by changing the duration of each period from 30 to 60 days (Fig. 2). This was done because prescription could be delayed in patients who do not regularly use their medication, and this could be misclassified as exposure to the medication. The case period was defined as the 60-day period before the index date. The 2 control periods were defined as the periods 120–180 days and 210–270 days before the index date.
We conducted subgroup analysis in individuals with a high risk of pneumonia, such as those with diabetes, documented disability due to brain lesions, and age over 65 years. We identified individuals with diabetes based on their ICD-10 codes (E10–14). We used the National Disability Registry System to identify stroke survivors with documented disability due to brain lesions. In South Korea, people with disabilities are registered through their local government as having 1 of 15 types of disabilities. If the severity of disability due to brain lesions such as stroke is high, the patient might be registered in the National Disability Registry System according to the brain lesion rather than the type of disability. Therefore, we classified individuals with severe disability due to brain disorders into a “documented disability” subgroup.

**Statistical analyses**
We performed conditional logistic regression analysis to estimate the association between antihypertensive use and the incidence of hospitalized pneumonia. Crude odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for the association between pneumonia and ACE inhibitors, ARBs, and other antihypertensives. Following adjustment for confounding factors, we calculated the adjusted OR. Confounding factors included statin, antipsychotic, and benzodiazepine use and outpatient visits. The crude and adjusted ORs were calculated using similar methods in the sensitivity and subgroup analyses. All statistical analyses were conducted using SAS software for Windows (SAS Institute Inc., Cary, NC, USA). A $P$ value $< 0.05$ was deemed statistically significant.

**Ethics statement**
The present study protocol was reviewed and approved by the Institutional Review Board of National Health Insurance Service Ilsan Hospital (approval No. 2019-01-034). No informed consent was required from patients due to the nature of public data from NHIS.

**RESULTS**

**Risk of hospitalized pneumonia**
We obtained the data of 2,907 stroke survivors who had been hospitalized for first-onset pneumonia. **Table 1** summarizes their general characteristics.

The use of ARBs lowered the risk of hospitalized pneumonia (adjusted OR [95% CI]: 0.718 [0.576–0.894]) in the patients with history of stroke. However, the use of ACE inhibitors and other antihypertensives were not associated with a change in the incidence of hospitalized pneumonia (adjusted ORs [95% CIs]: 0.902 [0.603–1.350] for ACE inhibitors and 0.788 [0.609–1.018] for other antihypertensive drugs; **Table 2**).

We obtained similar results in the sensitivity analysis (adjusted ORs [95% CIs]: 0.783 [0.619–0.992] for ARBs, 0.955 [0.635–1.436] for ACE inhibitors, and 0.884 [0.680–1.149] for other antihypertensive drugs; **Table 3**).

**Subgroup analysis**
The results of the subgroup analysis are presented in **Table 4**. In individuals aged $> 65$ years, a protective effect against hospitalized pneumonia was observed only in those who received ARBs (adjusted ORs [95% CIs]: 0.687 [0.536–0.880] for ARBs, 0.941 [0.596–1.487] for ACE inhibitors, and 0.857 [0.646–1.136] for other antihypertensives). This finding was similar to
that of the primary analysis. However, a reduced risk of hospitalized pneumonia in stroke survivors with diabetes mellitus was not noted for any type of antihypertensive (adjusted ORs [95% CIs]: 0.707 [0.481–1.040] for ARBs, 0.920 [0.460–1.840] for ACE inhibitors, and 0.864 [0.549–1.360] for other antihypertensives) and those with documented disability (adjusted ORs [95% CIs]: 0.841 [0.538–1.317] for ARBs, 1.410 [0.571–3.481] for ACE inhibitors, and 0.581 [0.334–1.011] for other antihypertensives).

Table 1. General characteristics of the patients with history of stroke (N = 2,907)

| Characteristics | No. (%) |
|-----------------|---------|
| Age             |         |
| Less than 60    | 277 (9.5) |
| 60–69           | 501 (17.2) |
| 70–79           | 1,149 (39.5) |
| 80 or more      | 981 (33.8) |
| Sex             |         |
| Male            | 1,518 (52.2) |
| Female          | 1,389 (47.8) |
| Diabetes        |         |
| Yes             | 788 (27.1) |
| No              | 2,119 (72.9) |
| Documented disability |         |
| Yes             | 698 (24.0) |
| No              | 2,209 (76.0) |
| Type of stroke  |         |
| Ischemic        | 2,095 (72.1) |
| Non-ischemic    | 812 (27.9) |
| Medication use  |         |
| ACE inhibitor   | 195 (6.7) |
| ARB             | 891 (30.65) |
| Other antihypertensives | 579 (19.88) |
| Statin          | 669 (23.01) |
| Antipsychotics  | 370 (12.73) |
| Benzodiazepine  | 858 (29.51) |

Patients registered for National Disability Registry System were classified as “documented disability” group. ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor blockers.

Table 2. Association between antihypertensives and pneumonia in stroke patients

| Antihypertensives | Crude OR (95% CI) | Adjusted OR (95% CI) |
|-------------------|-------------------|----------------------|
| ACE inhibitors    | 0.627 (0.435–0.902) | 0.902 (0.603–1.350) |
| ARBs              | 0.503 (0.416–0.609) | 0.718 (0.576–0.894) |
| Other antihypertensives | 0.593 (0.476–0.739) | 0.788 (0.609–1.018) |

Adjusted for ACE inhibitor, ARB, other antihypertensives, statin, antipsychotics, benzodiazepine, and outpatient visits. ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor blockers, OR = odds ratio, CI = confidence interval.

Table 3. Sensitivity analysis between antihypertensives and pneumonia

| Antihypertensives | Crude OR (95% CI) | Adjusted OR (95% CI) |
|-------------------|-------------------|----------------------|
| ACE inhibitors    | 0.704 (0.501–0.988) | 0.955 (0.635–1.436) |
| ARBs              | 0.559 (0.458–0.682) | 0.783 (0.619–0.992) |
| Other antihypertensives | 0.698 (0.566–0.859) | 0.884 (0.680–1.149) |

Adjusted for ACE inhibitor, ARB, other antihypertensives, statin, antipsychotics, benzodiazepine, and outpatient visits. ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor blockers, OR = odds ratio, CI = confidence interval.
DISCUSSION

The use of ARBs was associated with a reduced incidence of hospitalized pneumonia in patients with a history of stroke, while the use of ACE inhibitors and other antihypertensives did not exert any effect. Similar results were obtained in stroke survivors aged over 65 years. However, none of the antihypertensives reduced the risk of hospitalized pneumonia in stroke survivors with diabetes and documented disability. ARBs are commonly prescribed to patients with hypertension and cardiovascular diseases. They have been reported to have greater protective effects on pneumonia or lung injury than ACE inhibitors, which is consistent with our results. The exact mechanism remains unclear. However, the following mechanisms have been suggested for the effects of ACE inhibitors and ARBs in preventing pneumonia: ACE inhibitors act by blocking the conversion of angiotensin I to angiotensin II. This in turn inhibits the breakdown of bradykinin and substance P into inactive peptides, and elevated concentrations of bradykinin and substance P reportedly promote coughing and facilitate the swallowing reflex. In addition, ACE inhibitors and ARBs affect the renin-angiotensin system (RAS), which plays a major role in inflammation. The protective effect of ARBs could be explained by their role in the modulation of the inflammatory response via RAS blockade. Angiotensin II increases vascular permeability and promotes the production of inflammatory molecules and recruitment of leukocytes. ARBs block these actions, resulting in improvement in inflammatory or infectious lung conditions. Kim et al. and Lai et al. reported an association between ARB and a decreased incidence of pneumonia in patients with chronic obstructive pulmonary disease (COPD). This decreased incidence could be due to blockage of the renin-angiotensin system, which induces the release of inflammatory cytokines, or due to immunomodulation of the T-cell responses that mediate lung injury in COPD. Attenuation of bleomycin-induced pulmonary fibrosis via a decrease in the concentrations of inflammatory agents following ARB administration has been reported in mice. The protective effect of ARBs on pneumonia in stroke survivors could be explained by its anti-inflammatory effect on the lung.

However, subgroup analysis revealed different results from the primary analysis. ARBs did not reduce the incidence of pneumonia in patients with diabetes and documented disability. Diabetes is a risk factor for pneumonia requiring hospitalization. This can be attributed to the negative effect of hyperglycemia on innate immunity; hyperglycemia eventually leads to inflammation and provides a conducive environment for pathogens because of glucose.

### Table 4. Subgroup analysis between antihypertensives and pneumonia in people with diabetes, documented disability, and over 65 years old

| Subgroup                        | Antihypertensives | Crude OR (95% CI) | Adjusted OR (95% CI) |
|---------------------------------|-------------------|-------------------|----------------------|
| Patients with diabetes           | ACE inhibitors    | 0.600 (0.334–1.076) | 0.920 (0.460–1.840) |
|                                  | ARBs              | 0.531 (0.388–0.726) | 0.707 (0.481–1.040) |
|                                  | Other antihypertensives | 0.649 (0.455–0.927) | 0.864 (0.549–1.360) |
| Patients with documented disability* | ACE inhibitors    | 0.923 (0.421–2.023) | 1.410 (0.571–3.481) |
|                                  | ARBs              | 0.933 (0.363–0.783) | 0.841 (0.538–1.317) |
|                                  | Other antihypertensives | 0.532 (0.327–0.864) | 0.581 (0.334–1.011) |
| Over 65 years old                | ACE inhibitors    | 0.672 (0.448–1.009) | 0.941 (0.596–1.487) |
|                                  | ARBs              | 0.485 (0.393–0.599) | 0.687 (0.536–0.880) |
|                                  | Other antihypertensives | 0.622 (0.491–0.788) | 0.857 (0.646–1.136) |

Adjusted for ACE inhibitor, ARB, other antihypertensives, statin, antipsychotics, benzodiazepine, and outpatient visits.

ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor blockers, OR = odds ratio, CI = confidence interval.

*Patients registered for National Disability Registry System were classified as “documented disability” group.
secretion in the airways. Stroke survivors with documented disability have severe
disability, and they are likely to have several risk factors for pneumonia, including dysphagia,
cognitive impairment, or loss of consciousness. These results imply that the protective effect
of ARBs might be decreased in patients with stroke who have a high risk of pneumonia.

As observed in the subgroup analysis, several studies have reported differences in the
protective effects of antihypertensives depending on the population groups. Two case-
crossover studies conducted in Taiwan using data from the Taiwanese Longitudinal Health
Insurance Database reported that the use of ACE inhibitors and ARBs did not reduce the
risk of pneumonia in the general population. However, ACE inhibitors have been found
to exert significant protective effects against pneumonia requiring hospitalization in stroke
survivors. Likewise, van de Garde et al. reported that the use of ACE inhibitors was not
beneficial for reducing pneumonia in the general White population, but it exhibited a
protective effect against pneumonia in patients with diabetes. Lee at al. reported that the
hazard ratio of ARBs in patients with hospitalized pneumonia in the general population is
0.853 (0.820–0.887), but this potential beneficial effect was not observed in patients with
coronavirus disease 2019.

In our study, the use of ACE inhibitors was not associated with a reduced incidence of
hospitalized pneumonia in patients with stroke. Several studies have reported beneficial
effects of ACE inhibitors on the risk of pneumonia in stroke survivors, which is inconsistent
with our findings. A systematic review and meta-analysis of 18 randomized controlled trials,
11 cohort studies, 2 nested case-control studies, and 6 case-control studies of patients with
a history of stroke reported that ACE inhibitors reduced the risk of pneumonia by 34% (OR,
0.66). In contrast, a randomized controlled trial showed that the use of ACE inhibitors
increased the incidence of pneumonia in patients with neurologic dysphagia; tube-fed
patients with neurologic dysphagia allocated to the lisinopril group (2.5 mg daily) (n = 38) and
placebo group (n = 33) were compared, and the treatment group was found to have a higher
6-month mortality and probability of pneumonia or death than the placebo group. Therefore,
further investigation is needed to identify factors that can reduce the incidence of pneumonia.

According to the results of previous studies and our study, the use of ARBs or ACE inhibitors
cannot reduce the risk of pneumonia in healthy individuals or those with a high degree of
comorbidity, but they could exhibit a protective effect in patients with a minor degree of
comorbidity. However, the results differ from study to study.

This study has several limitations. First, we only included patients with pneumonia who
required hospitalization and excluded those who were treated on an outpatient basis. Thus,
patients with stroke who had atypical pneumonia, which can be treated in an outpatient clinic,
were not included. In addition, we could not determine whether the patients were vaccinated
against pneumonia and the cause of the pneumonia, such as community-acquired pneumonia,
aspiration pneumonia, ventilator-associated pneumonia, or bacterial or viral pneumonia.
Third, we did not consider the use of corticosteroids or immune-suppressants as confounding
factors, although these factors could increase the incidence of pneumonia. Nevertheless, this
was the first study to show an association between antihypertensive use and the incidence of
hospitalized pneumonia using data from a Korean national database of stroke survivors.

In conclusion, the use of ARBs was associated with a reduced incidence of hospitalized
pneumonia in Korean patients with history of stroke. However, there was no significant
preventive effect in patients with severe post-stroke disability. Further large-scale studies on healthy individuals are needed to investigate the relationship between antihypertensive use and the incidence of pneumonia.

SUPPLEMENTARY MATERIAL

Supplementary Table 1
2019 Korean medication list published by the National Health Insurance Review and Assessment Service

Click here to view

REFERENCES

1. Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J, et al. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. *Am J Respir Crit Care Med* 2004;169(9):1041-5. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/15142195/) | [CROSSREF](https://doi.org/10.1164/ajrccm.169.9.15142195)

2. Statistics Korea. 2020 cause of death statistics. http://kosis.kr. Updated 2021. Accessed February 24, 2022.

3. Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D. Post-stroke infection: a systematic review and meta-analysis. *BMC Neurol* 2011;11(1):110. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/21780808/) | [CROSSREF](https://doi.org/10.1186/1471-2379-11-110)

4. Elkind MS, Boehme AK, Smith CI, Meisel A, Buckwalter MS. Infection as a stroke risk factor and determinant of outcome after stroke. *Stroke* 2020;51(10):3156-68. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/32093841/) | [CROSSREF](https://doi.org/10.1161/STROKEAHA.120.032787)

5. Liu CL, Shau WY, Wu CS, Lai MS. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients. *J Hypertens* 2012;30(11):2223-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/22948112/) | [CROSSREF](https://doi.org/10.1007/s10992-012-1427-9)

6. Lee JS, Chui PY, Ma HM, Au yeung TW, Ng C, Law T, et al. Does low dose angiotensin converting enzyme inhibitor prevent pneumonia in older people with neurologic dysphagia--a randomized placebo-controlled trial. *J Am Med Dir Assoc* 2015;16(8):702-7. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/26325822/) | [CROSSREF](https://doi.org/10.1016/j.jamda.2015.02.018)

7. Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. *BMJ* 2012;345:e4260. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/22343004/) | [CROSSREF](https://doi.org/10.1136/bmj.e4260)

8. Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. *Int J Epidemiol* 2017;46(2):e15. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/27882949/) | [CROSSREF](https://doi.org/10.1093/ije/dyw268)

9. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. *Am J Epidemiol* 1991;133(2):144-53. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/1686018/) | [CROSSREF](https://doi.org/10.1093/aje/133.2.144)

10. Mandell LA, Niederman MS. Aspiration pneumonia. *N Engl J Med* 2019;380(7):651-63. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/30372636/) | [CROSSREF](https://doi.org/10.1056/NEJMra1806228)

11. Herzig SJ, LaSalvia MT, Naidus E, Rothberg MB, Zhou W, Gurwitz JH, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. *J Am Geriatr Soc* 2017;65(12):2580-6. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/28953509/) | [CROSSREF](https://doi.org/10.1111/jgas.13887)

12. Boivin Z, Perez MF, Atuegwu NC, Metersky M, Alvarez CA, Anzueto A, et al. Association of atypical antipsychotics and mortality for patients hospitalised with pneumonia. *EBJ Open Res* 2019;5(4):e00223-2018. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/31471226/) | [CROSSREF](https://doi.org/10.1186/s41879-019-00224-3)

13. Sun GQ, Zhang L, Zhang LN, Wu Z, Hu DF. Benzodiazepines or related drugs and risk of pneumonia: a systematic review and meta-analysis. *Int J Geriatr Psychiatry* 2019;34(4):513-21. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/30309945/) | [CROSSREF](https://doi.org/10.1002/gps.4973)
14. Kang JH, Kao LT, Lin HC, Wang TJ, Yang TY. Do outpatient statins and ACEIs/ARBs have synergistic effects in reducing the risk of pneumonia? A population-based case-control study. PLoS One 2018;13(6):e0199981.

15. Mortensen EM, Nakashima B, Cornell J, Copeland LA, Pugh MJ, Anzueto A, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012;55(11):1466-73.

16. Shah S, McArthur E, Farag A, Narrey M, Fleet JL, Knoll GA, et al. Risk of hospitalization for community acquired pneumonia with renin-angiotensin blockade in elderly patients: a population-based study. PLoS One 2014;9(10):e110165.

17. Kim J, Lee JK, Heo EY, Chung HS, Kim DK. The association of renin-angiotensin system blockades and pneumonia requiring admission in patients with COPD. Int J Chron Obstruct Pulmon Dis 2016;11:2159-66.

18. Lai CC, Wang YH, Wang CY, Wang HC, Yu CJ, Chen L. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis 2018;13:867-74.

19. Nakayama K, Sekizawa K, Sasaki H. ACE inhibitor and swallowing reflex. Chest 1998;113(5):1425.

20. Omboni S, Borghi C. Zofenopril and incidence of cough: a review of published and unpublished data. Ther Clin Risk Manag 2011;7:459-71.

21. Barnes RA. Pneumonia and ACE inhibitors--and cough. BMJ 2012;345:e4566.

22. Moriya T, Nakayama K, Nakamura S, Mochizuki A, Ofuji T, Shirato T, et al. Enhancement of swallowing motor activity by the ACE inhibitor imidapril in an arterially perfused rat preparation. Eur J Pharmacol 2019;861:172601.

23. Hsu WT, Galm BP, Schrank G, Hsu TC, Lee SH, Park JY, et al. Effect of renin-angiotensin-aldosterone system inhibitors on short-term mortality after sepsis: a population-based cohort study. Hypertension 2020;75(2):483-91.

24. Lee HY, Ahn J, Park J, Kang CK, Won SH, Kim DW, et al. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia. Korean J Intern Med 2021;36(3):617-28.

25. Nahmod KA, Nahmod VE, Szvalb AD. Potential mechanisms of AT1 receptor blockers on reducing pneumonia-related mortality. Clin Infect Dis 2013;56(8):1193-4.

26. Tanaka J, Tajima S, Asakawa K, Sakagami T, Moriyama H, Takada T, et al. Preventive effect of irbesartan on bleomycin-induced lung injury in mice. Respir Investig 2013;51(2):76-83.

27. van de Garde EM, Souverein PC, van den Bosch JM, Leufkens HG. Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. J Hypertens 2007;25(1):235-9.

28. Valerius NH, Eff C, Hansen NE, Karle H, Nerup J, Søeberg B, et al. Neutrophil and lymphocyte function in patients with diabetes mellitus. Acta Med Scand 1982;211(6):463-7.

29. Marhofer W, Stein M, Maesser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992;15(2):256-60.

30. Liu CL, Shau WY, Chang CH, Wu CS, Lai MS. Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. J Epidemiol 2013;23(9):344-50.

31. van de Garde EM, Souverein PC, van den Bosch JM, Deneer VH, Leufkens HG. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J 2006;27(6):1217-22.
32. Sekizawa K, Matsui T, Nakagawa T, Nakayama K, Sasaki H. ACE inhibitors and pneumonia. *Lancet* 1998;352(9133):1069.

33. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Angiotensin-converting enzyme inhibitor use and pneumonia risk in community-dwelling older adults: results from a population-based case-control study. *Pharmacoepidemiol Drug Saf* 2012;21(11):1173-82.

34. Wang HC, Lin CC, Lau CI, Chang A, Kao CH. Angiotensin-converting enzyme inhibitors and bacterial pneumonia in patients with Parkinson disease. *Mov Disord* 2015;30(4):593-6.